SAO PAULO, March 12, 2026, 12:47 BRT
Banco Bradesco’s preferred ADRs trading in the U.S. slid roughly 5% to $3.65 on Thursday, caught up in a wider rout for Brazilian bank stocks. Shares of Itaú Unibanco and Santander Brasil also lost ground, signaling the move wasn’t isolated to Bradesco.
Timing is a factor here. Brazil’s central bank holds its meeting on March 17-18, and February’s inflation numbers sent mixed signals: annual inflation dropped to 3.81%, the lowest level since April 2024, yet the monthly increase outpaced forecasts. Traders are divided—some expect a 25-basis-point cut, others bet on 50. (A basis point is one-hundredth of a percentage point.) Oil prices, according to Banco Daycoval economist Julio Barros, tilt expectations toward steady rates. Capital Economics’ Liam Peach calls the situation “a lot of uncertainty.” Reuters
The slide accelerated in New York. Oil climbing toward $100 a barrel and renewed jitters over private credit sent investors fleeing from banks and riskier corners of Wall Street’s financial sector.
Bradesco had some fresh news in the mix. In a March 11 filing, shareholders gave the green light to a 6.67 billion-real capital boost—reshuffling part of a reserve into capital, which brings the total up to 93.77 billion reais, all without releasing any new shares. They also signed off on the 2025 financial statements and locked in management compensation for 2026 at that same meeting.
Bradesco continues to overhaul its healthcare portfolio. On March 6, the bank said it signed an amendment—terms untouched—in its plan to bring its healthcare businesses under Odontoprev. That company is set to take on a new name: Bradsaúde.
Executives are calling this deal a scale move. Chairman Luiz Carlos Trabuco Cappi described the business as having “scale, momentum and strategic relevance,” while Chief Executive Marcelo Noronha put the potential value for the new company somewhere “between R$40 billion and R$50 billion.” Incoming chief Carlos Marinelli added that it would launch with “zero leverage.” Bradesco’s materials for investors point to a projected 3.6 billion reais in net income and a 24% return on equity, measuring profit against shareholder capital. Mziq API
But complications remain. The Bradsaúde deal faces more regulatory hurdles, while Brazil’s central bank has flagged concerns about inflation tied to rising oil prices—a sign that lenders could see the interest rate environment pivot without much warning.
Thursday’s drop appears tied more to broad macro and sector dynamics than to anything specific at Bradesco. Shares of other Brazilian bank ADRs slipped about 4% to 6%. For Bradesco, next week’s rate call and the healthcare shake-up stand out as the next major catalysts.
